Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

 

COLUMVI in combination with gemcitabine and oxaliplatin (GemOx) is indicated for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).1

 

COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.1

 

nil
Prescribing Information
Treatment pathway 2L: COLUMVI + GemOx 3L+: COLUMVI monotherapy

NICE recommends COLUMVI + GemOx for ASCT-ineligible R/R DLBCL NOS2

Glofitamab plus gemcitabine and oxaliplatin can be used as an option to treat R/R DLBCL NOS in adults when:

  • they have had 1 line of treatment only, and
  • they are not eligible for ASCT

R/R DLBCL is an area of unmet need, with poor survival outcomes for those refractory to immunochemotherapy.3 Around half of the patients seeking second line (2L) treatments are ineligible for ASCT.4 
 

Despite new treatment options for R/R DLBCL, the unmet need remains for 2L DLBCL patients who are transplant-ineligible.

 

COLUMVI + GemOx can now be used as a 2L treatment routinely across the NHS (except in Scotland) in adults with R/R DLBCL NOS who are not eligible for ASCT.2

 

The STARGLO study compared COLUMVI + GemOx with rituximab + GemOx.5
Expert perspectives on COLUMVI + GemOx

 

Watch three leading UK lymphoma experts, who were investigators in the registration study (STARGLO), discuss evolving treatment pathways, trial data, and real-world implementation.

 

  • Professor Chris Fox, Consultant Haematologist, Nottingham University Hospital
  • Dr Cathy Burton, Consultant Haematologist, St. James's University Hospital, Leeds
  • Dr Will Townsend, Consultant Haematologist, University College London Hospital

 

For UK prescribing information, please click here or scan the QR code in the videos.

We are dedicated to supporting HCPs to achieve optimal patient outcomes, If you have any questions about our products, from practical matters to understanding the data, please do not hesitate to contact us.

Contact our team for support on implementing the COLUMVI + GemOx regimen
Explore more
Products Content page
Review the use of COLUMVI as monotherapy for R/R DLBCL
Columvi Product
Explore where COLUMVI fits in the DLBCL treatment landscape
Hematology Oncology Content page
Explore the Roche haematology portfolio

Abbreviations:


2L, second line; 3L+, third line and beyond; ASCT, autologous stem cell transplant; DLBCL, diffuse large B-cell lymphoma; GemOx, gemcitabine and oxaliplatin; HCP, healthcare professional; NICE, National Institute for Health and Care Excellence; NOS, not otherwise specified; R/R, relapsed/refractory.

References:

  1. COLUMVI Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. Technology appraisal guidance 1113. https://www.nice.org.uk/guidance/ta1113 Published: 03 December 2025.
  3. Crump M, et al. Blood 2017;130(16):1800–1808.
  4. Westin J, Sehn LH. Blood 2022;139(18):2737–2746.
  5. Abramson J, et al. Lancet 2024;404:1940–1954.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.